Specific populations

Use of the Omnipod 5 closed-loop insulin delivery system reduces diabetes distress and improves quality of life, particularly for the carers of children with type 1 diabetes, research shows.

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

Use of continuous glucose monitoring within the first month of diagnosis is associated with an improvement in glycemic control among youth with type 1 diabetes, indicate findings from the 4T study.

A closed-loop system with an artificial intelligence component that rapidly detects when the user is eating a meal may offer a route towards fully closed-loop insulin delivery, shows a small crossover trial in adolescents and young adults.

Use of an insulin pump is not associated with better glycemic control than multiple daily injections among children and adolescents with type 1 diabetes, indicate real-world study results.

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

The use of continuous glucose monitoring does not increase time in range in young children with type 1 diabetes, but may improve other glycemic indices, researchers report.

US researchers have identified racial disparities in the receipt of diabetes technologies among young adults with type 1 diabetes.

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.

Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.

Click through to read more on this announcement

Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.

The Dexcom G6 continuous glucose monitoring system may be a good option to help young adults with type 1 diabetes control their blood glucose, show the results of the MILLENNIAL trial.

Involving older children with type 1 diabetes in the decision-making process about starting continuous glucose monitoring may help to ensure that they persist with the technology, report researchers.

Continuous glucose monitoring is well accepted and reduces time in hypoglycemia among older individuals with type 1 diabetes, report researchers in JAMA.

Impaired awareness of hypoglycemia is associated with an increased risk for severe hypoglycemia and increased fear of hypoglycemia in pregnant women with type 1 diabetes, shows a post-hoc analysis of CONCEPTT data.

The Omnipod Horizon closed-loop system has delivered good glucose control in its first outpatient study, the investigators report.

The Medtronic MiniMed Advanced Hybrid Closed-Loop system delivers better glycemic control than the currently approved 670G system, shows the international FLAIR trial.

Age at type 1 diabetes diagnosis does not appear to affect glycemic control and comorbidity once disease is established, but important differences occur between age groups at the time of diagnosis, US study data show.

A survey of US adolescents with type 1 diabetes has found that cost, negative attitudes towards wearing a device, and technology-related anxiety all act as obstacles preventing the use of devices in this age group.